Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives

Digestive and Liver Disease

Volumn 38, Issue 11, 2006, Pages 789-801

  Federico, A ^a   Trappoliere, M ^a   Loguercio, C ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Clinical management; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; BETAINE; BIGUANIDE DERIVATIVE; CLOFIBRATE; CURCUMIN; GEMFIBROZIL; GLUCAGON LIKE PEPTIDE 1; INCRETIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLCHOLINE; PIOGLITAZONE; PIRFENIDONE; PLACEBO; PROBUCOL; PROTECTIVE AGENT; ROSIGLITAZONE; ROSUVASTATIN; SELENIUM; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ADIPOSE TISSUE; BARIATRIC SURGERY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TOXICITY; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; RISK ASSESSMENT; SHORT SURVEY; STEATOSIS;

ANTI-OBESITY AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; BIOPSY; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; DIET; FATTY LIVER; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; LIVER; OBESITY;

EID: 33748946051     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.04.009     Document Type: Short Survey

References (149)

1. Festi D., Colecchia A., Sacco T., Bondi M., Roda E., and Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 5 (2004) 27-42
2. Caldwell S.H., Crespo D.M., Kang H.S., and Al-Osaimi A.M. Obesity and hepatocellular carcinoma. Gastroenterology 127 (2004) S97-S103
3. Portincasa P., Grattagliano I., Palmieri V.O., and Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem 38 (2005) 203-217
4. Stroffolini T., Sagnelli E., Mele A., Craxì A., and Almasio P. The aetiology of chronic hepatitis in Italy: results from a multicentre national study. Digest Liver Dis 36 (2004) 829-833
5. Sagnelli E., Stroffolini T., Mele A., Almasio P., Coppola N., Ferrigno L., et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 75 (2005) 522-527
6. Bellentani S., Bedogni G., Miglioli L., and Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 16 (2004) 1087-1093
7. Sorrentino P., Tarantino G., Conca P., Perrella A., Terracciano M.L., Vecchione R., et al. Silent non-alcoholic fatty liver disease: a clinical-histological study. J Hepatol 41 (2004) 751-757
8. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 (2004) 2362-2374
9. Loguercio C., De Girolamo V., De Sio I., Tuccillo C., Ascione A., Baldi F., et al. Non-alcoholic fatty liver disease in an area of Southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 35 (2001) 568-574
10. Loguercio C., De Simone T., D'Auria M.V., De Sio I., Federico A., Tuccillo C., et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Digest Liver Dis 36 (2004) 398-405
11. Sanyal A.J. Review article: non-alcoholic fatty liver disease and hepatitis C-risk factors and clinical implications. Aliment Pharmacol Ther 22 (2005) 48-51
12. Powell E.E., Jonsson J.R., and Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 42 (2005) 5-13
13. Hu K.Q., Kyulo N.L., Esrailian E., Thompson K., Chase R., Hillebrand D.J., et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 40 (2004) 147-154
14. Bressler B.L., Guindi M., Tomlinson G., and Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003) 639-644
15. Sud A., Hui J.M., Farrell G.C., Bandara P., Kench J.G., Fung C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39 (2004) 1239-1247
16. Narita R., Abe S., Kihara Y., Akiyama T., Tabaru A., and Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 41 (2004) 132-138
17. Adams L.A., Lymp J.F., Sauver J.St., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
18. Cinar K., Coban S., Idilman R., Tuzun A., Sarioglu M., Bektas M., et al. Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?. J Gastroenterol Hepatol 21 (2006) 169-173
19. Cortez-Pinto H., Carneiro de Moura M., and Day C.P. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 44 (2006) 197-208
20. Bardella M.T., Valenti L., Pagliari C., Peracchi M., Fare M., Fracanzani A.L., et al. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Digest Liver Dis 36 (2004) 333-336
21. Bonkovsky H.L., and Lambrecht R.W. Iron-induced liver injury. Clin Liver Dis 4 (2000) 409-429
22. Pittler M.H., and Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 18 (2003) 451-471
23. Rubenstein J.H., and Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20 (2004) 373-380
24. Ataseven H., Yildirim M.H., Yalniz M., Bahcecioglu I.H., Celebi S., and Ozercan I.H. The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol Belg 68 (2005) 221-225
25. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
26. Ruhl C.E., and Everhart J.E. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 124 (2003) 1821-1829
27. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
28. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 521-533
29. Haque M., and Sanyal A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 16 (2002) 709-731
30. Laine F., Bendavid C., Moirand R., Tessier S., Perrin M., Guillygomarc'h A., et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 39 (2004) 1639-1646
31. Naveau S., Raynard B., Ratziu V., Abella A., Imbert-Bismut F., Messous D., et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3 (2005) 167-174
32. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
33. Angulo P., Alba L.M., Petrovic L.M., Adams L.A., Lindor K.D., and Jensen M.D. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 41 (2004) 943-949
34. Comlekci A., Akpinar H., Yesil S., Okan I., Ellidokuz E., Okan A., et al. Serum leptin levels in patients with liver cirrhosis and chronic viral hepatitis. Scand J Gastroenterol 38 (2003) 779-786
35. Rubbia-Brandt L., and Hadengue A. Nonalcoholic fatty liver: does it have to be biopsed?. Rev Med Suisse 1 (2005) 2804-2808
36. Tilg H., and Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 148-155
37. Adams L.A., Sanderson S., Lindor K.D., and Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005) 132-138
38. Luyckx F.H., Lefebvre P.J., and Scheen A.J. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 26 (2000) 98-106
39. Dumas J.F., Roussel D., Simard G., Douay O., Foussard F., Malthiery Y., et al. Food restriction affects energy metabolism in rat liver mitochondria. Biochim Biophys Acta 1670 (2004) 126-131
40. Tirosh O., Aronis A., Zusman I., Kossoy G., Yahav S., Shinder D., et al. Mitochondrion-mediated apoptosis is enhanced in long-lived alpha-MUPA transgenic mice and calorically restricted wild-type mice. Exp Gerontol 38 (2003) 955-963
41. Ramesh S., and Sanyal A.J. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol 42 (2005) S2-S12
42. Jaskiewicz K., Raczynska S., Rzepko R., and Sledzinski Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 51 (2006) 21-26
43. Mattar S.G., Velcu L.M., Rabinovitz M., Demetris A.J., Krasinskas A.M., Barinas-Mitchell E., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242 (2005) 610-617
44. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 130 (2006) 1848-1852
45. Stratopoulos C., Papakonstantinou A., Terzis I., Spiliadi C., Dimitriades G., Komesidou V., et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 15 (2005) 1154-1160
46. Barker K.B., Palekar N.A., Bowers S.P., Goldberg J.E., Pulcini J.P., and Harrison S.A. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 101 (2006) 368-373
47. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
48. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37 (2003) 909-916
49. Huang M.A., Greenson J.K., Chao C., Anderson L., Peterman D., Jacobson J., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100 (2005) 1072-1081
50. Solga S., Alkhuraishe A.R., Clark J.M., Torbenson M., Greenwald A., Diehl A.M., et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 49 (2004) 1578-1583
51. Koteish A., and Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 679-690
52. Hickman I.J., Jonsson J.R., Prins J.B., Ash S., Purdie D.M., Clouston A.D., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53 (2004) 413-419
53. Goodpaster B.H., Katsiaras A., and Kelley D.E. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 52 (2003) 2191-2197
54. Bergasa N.V., Mehlman J., and Bir K. Aerobic exercise: a potential therapeutic intervention for patients with liver disease. Med Hypotheses 62 (2004) 935-941
55. Ward A.M., Syddall H.E., Wood P.J., Dennison E.M., and Phillips D.I. Central hypothalamic-pituitary-adrenal activity and the metabolic syndrome: studies using the corticotrophin-releasing hormone test. Metabolism 53 (2004) 720-726
56. Kugelmas M., Hill D.B., Vivian B., Marsano L., and McClain C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38 (2003) 413-419
57. Harrison S.A., Fincke C., Helinski D., Torgerson S., and Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20 (2004) 623-628
58. Sabuncu T., Nazligul Y., Karaoglanoglu M., Ucar E., and Kilic F.B. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 12 (2003) 189-192
59. Rotella C.M., Pala L., and Mannucci E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 28 (2005) 746-758
60. Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23 (1996) 1464-1467
61. Basaranoglu M., Acbay O., and Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31 (1999) 384-389
62. Kiyici M., Gulten M., Gurel S., Nak S.G., Dolar E., Savci G., et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17 (2003) 713-718
63. Merat S., Malekzadeh R., Sohrabi M.R., Sotoudeh M., Rakhshani N., Sohrabpour A.A., et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 38 (2003) 414-418
64. Ahmed MH. Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers. Med Hypotheses 2005 [Epub ahead of print].
65. Mendez-Sanchez N., Chavez-Tapia N.C., Villa A.R., Sanchez-Lara K., Zamora-Valdes D., Ramos M.H., et al. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 11 (2005) 1737-1741
66. Targher G., Bertolini L., Scala L., Poli F., Zenari L., and Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol 61 (2004) 700-703
67. Pagano C., Soardo G., Esposito W., Fallo F., Basan L., Donnini D., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152 (2005) 113-118
68. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
69. Hasegawa G., Ohta M., Ichida Y., Obayashi H., Shigeta M., Yamasaki M., et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol 42 (2005) 104-109
70. Ballantyne G.H., Gumbs A., and Modlin I.M. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 15 (2005) 692-699
71. Banerjee R.R., Rangwala S.M., Shapiro J.S., Rich A.S., Rhoades B., Qi Y., et al. Regulation of fasted blood glucose by resistin. Science 303 (2004) 1195-1198
72. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., and DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28 (2004) 783-789
73. Muse E.D., Obici S., Bhanot S., Monia B.P., McKay R.A., Rajala M.W., et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114 (2004) 232-239
74. Kim H.J., Lee K.E., Kim D.J., Kim S.K., Ahn C.W., Lim S.K., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 164 (2004) 2169-2175
75. Gupte P., Amarapurkar D., Agal S., Baijal R., Kulshrestha P., Pramanik S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19 (2004) 854-858
76. Friis-Liby I., Aldenborg F., Jerlstad P., Rundstrom K., and Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 39 (2004) 864-869
77. Juhan-Vague I., Morange P.E., and Alessi M.C. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 32 (2002) 269-273
78. Targher G., Bertolini L., Padovani R., Zenari L., Zoppini G., and Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 (2004) 2498-2500
79. Volzke H., Robinson D.M., Kleine V., Deutscher R., Hoffmann W., Ludemann J., Schminke U., Kessler C., and John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 11 (2005) 1848-1853
80. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278 (2003) 34268-34276
81. Moller D.E., and Berger J.P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27 (2003) S17-S21
82. Yeon J.E., Choi K.M., Baik S.H., Kim K.O., Lim H.J., Park K.H., et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 19 (2004) 799-804
83. Yu S., Rao S., and Reddy J.K. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 3 (2003) 561-572
84. Hashimoto T., Cook W.S., Qi C., Yeldandi A.V., Reddy J.K., and Rao M.S. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275 (2000) 28918-28928
85. Larter C.Z., and Farrell G.C. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?. J. Hepatology 44 (2006) 253-261
86. Nair S., Diehl A.M., Wiseman M., Farr Jr. G.H., and Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20 (2004) 23-28
87. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19 (2004) 537-544
88. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005) 1082-1090
89. Schwimmer J.B., Middleton M.S., Deutsch R., and Lavine J.E. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 21 (2005) 871-879
90. Kawaguchi K., Sakaida I., Tsuchiya M., Omori K., Takami T., and Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 315 (2004) 187-195
91. Sanyal A.J., Mofrad P.S., Contos M.J., Sargeant C., Luketic V.A., Sterling R.K., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 (2004) 1107-1115
92. Lutchman G., Promrat K., Kleiner D.E., Heller T., Ghany M.G., Yanovski J.A., et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4 (2006) 1048-1052
93. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
94. Ip E., Farrell G., Hall P., Robertson G., and Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39 (2004) 1286-1296
95. Ong J.P., and Younossi Z.M. Approach to the diagnosis and treatment of non-alcoholic fatty liver disease. Clin Liver Dis 9 (2005) 617-634
96. Mendes F.D., and Lindor K.D. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opin Invest Drugs 14 (2005) 29-35
97. Sass D.A., Chang P., and Chopra K.B. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 50 (2005) 171-180
98. Solga S.F., and Diehl A.M. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 38 (2003) 681-687
99. Solga S.F., and Diehl A.M. Gut flora-based therapy in liver disease? The liver cares about the gut. Hepatology 39 (2004) 1197-2000
100. Loguercio C., De Simone T., Federico A., Terracciano F., Tuccillo C., Di Chicco M., et al. Gut-liver axis: a new point of attack to treat chronic liver damage?. Am J Gastroenterol 97 (2002) 2144-2146
101. Nair S., Cope K., Risby T.H., and Diehl A.M. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 1200-1204
102. Nardone G., and Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol 38 (2004) S121-S122
103. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 (2003) 343-350
104. Loguercio C., Federico A., Tuccillo C., Terracciano F., D'Auria M.V., De Simone C., et al. Beneficial effects of a probiotic VSL(3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39 (2005) 540-543
105. Soza A., Riquelme A., Gonzalez R., Alvarez M., Perez-Ayuso R.M., Glasinovic J.C., et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 50 (2005) 1136-1140
106. Fan J.G., Xu Z.J., and Wang G.L. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitismodel. World J Gastroenterol 11 (2005) 5053-5056
107. Galli A., Svegliati-Baroni G., Ceni E., Milani S., Ridolfi F., Salzano R., et al. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 41 (2005) 1074-1084
108. Pessayre D., and Fromenty B. NASH: a mitochondrial disease. J Hepatol 42 (2005) 928-940
109. Loguercio C., and Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 34 (2003) 1-10
110. Abdelmalek M.F., Angulo P., Jorgensen R.A., Sylvestre P.B., and Lindor K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96 (2001) 2711-2717
111. Miglio F., Rovati L.C., Santoro A., and Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 50 (2000) 722-727
112. Oliveira C.P., Gayotto L.C., Tatai C., Nina B.I., Lima E.S., Abdalla D.S., et al. Vitamin C and Vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr J 2 (2003) 9-19
113. Harrison S.A., Torgerson S., Hayashi P., Ward J., and Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98 (2003) 2485-2490
114. Hasegawa T., Yoneda M., Nakamura K., Makino I., and Terano A. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15 (2001) 1667-1672
115. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136 (2000) 734-738
116. Buchman A.L., Dubin M., Jenden D., Moukarzel A., Roch M.H., Rice K., et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 102 (1992) 1363-1370
117. Baybutt R.C., and Molteni A. Dietary beta-carotene protects lung and liver parenchyma of rats treated with monocrotaline. Toxicology 137 (1999) 69-80
118. Nakano H., Nagasaki H., Barama A., Boudjema K., Jaeck D., Kumada K., et al. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. Hepatology 26 (1997) 670-678
119. Hiroko M., Kazuo I., Yuji N., Saburo H., Yukihiro I., and Norifumi K. Sulfur-containing amino acids attenuate the development of liver fibrosis in rats through down-regulation of stellate cell activation. J Hepatol 40 (2004) 917-925
120. Shalan M.G., Mostafa M.S., Hassouna M.M., El-Nabi S.E., and El-Refaie A. Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements. Toxicology 206 (2005) 1-15
121. Parés A., Planas R., Torres M., Caballeria J., Viver J.M., Acero D., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28 (1998) 615-621
122. Valenzuela A., Lagos C., Schmidt K., and Videla L. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol 34 (1985) 2209-2212
123. Wellington K., and Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 15 (2001) 465-489
124. Di Sario A., Bendie E., Taffetani S., Omenetti A., Candelaresi C., Marzioni M., et al. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Digest Liver Dis 37 (2005) 869-876
125. Trappoliere M., Tuccillo C., Federico A., Di Leva A., Niosi M., D'Alessio C., et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 9 (2005) 299-304
126. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non alcoholic fatty liver disease: preliminary observations. Letter to Gut [in press].
127. Trauner M., and Graziadei I.W. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13 (1999) 979-996
128. Lindor K.D., Kowdley K.V., Heathcote J.E., Harrison M.E., Jorgensen R., Mgulo P., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 (2004) 770-778
129. Kaibori M., Yanagida H., Uchida Y., Yokoigawa N., Kwon A.H., Okumura T., et al. Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats. Transplant Proc 36 (2004) 1973-1974
130. Di Sario A., Bendia E., Svegliati Baroni G., Ridolfi F., Casini A., Ceni E., et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37 (2002) 584-591
131. Xu J., Fu Y., and Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 285 (2003) 20-30
132. Fort J., Oberti F., Pilette C., Veal N., Gallois Y., Douay O., et al. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 28 (1998) 1525-1531
133. Park E.J., Ko G., Kim J., and Sohn D.H. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biol Pharm Bull 20 (1997) 417-420
134. Ma X., Zhao J., and Lieber C.S. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 24 (1996) 604-613
135. Oberti F., Pilette C., Rifflet H., Maiga M.Y., Moreau A., Gallois Y., et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. Hepatology 26 (1997) 1363-1371
136. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005;CD002148.
137. Morgan T.R., Weiss D.G., Nemchausky B., Schiff E.R., Anand B., Simon F., et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 128 (2005) 882-890
138. Sakaida I., Hironaka K., Kimura T., Terai S., Yamasaki T., and Okita K. Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell. Life Sci 74 (2004) 2251-2263
139. Kusunose M., Qiu B., Cui T., Hamada A., Yoshioka S., Ono M., et al. Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine-induced liver injury rats. Biol Pharm Bull 25 (2002) 1417-1421
140. Wright M.C., Issa R., Smart D.E., Trim N., Murray G.I., Primrose J.N., et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121 (2001) 685-698
141. Orr J.G., Leel V., Cameron G.A., Marek C.J., Haughton E.L., Elrick L.J., et al. Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology 40 (2004) 232-242
142. Wei Y.H., Jun L., and Qiang C.J. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci 49 (2004) 1589-1594
143. Guo L., Richardson K.S., Tucker L.M., Doll M.A., Hein D.W., and Arteel G.E. Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 40 (2004) 583-589
144. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
145. Masini A., Ceccarelli D., Giovannini F., Montosi G., Garuti C., and Pietrangelo A. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J Bioenerg Biomembr 32 (2000) 175-182
146. Jia J.D., Bauer M., Cho J.J., Ruehl M., Milani S., Boigk G., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1 and TIMP-1. J Hepatol 35 (2001) 392-398
147. Trappoliere M., Federico A., Tuccillo C., de Sio I., Di Leva A., Niosi M., et al. Effects of a new pharmacological complex (silybin+vitamin E+phospholipids) on some markers of metabolic syndrome and of a liver fibrosis in patients with non-alcoholic fatty liver disease: a preliminary open pilot study. Minerva Gastroenterol Dietol 51 (2005) 193-199
148. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) 99-112
149. Zelber-Sagi S., Kessler A., Brazowsky E., Webb M., Lurie Y., Santo M., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4 (2006) 639-644